[HTML][HTML] Protection against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron SARS-CoV-2 infection among health-care …
…, S Barkati, C Sauvageau, N Brousseau… - The Lancet Infectious …, 2023 - thelancet.com
Background There is a paucity of data on vaccine-induced or infection-induced (hybrid or
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the …
Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec …
Background The Canadian COVID-19 immunization strategy deferred second doses and
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by vaccine type (…
[PDF][PDF] Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
…, R Bazin, M Dubé, G De Serres, N Brousseau… - Cell host & …, 2022 - cell.com
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …
administered three weeks apart. However, some public health authorities spaced these …
Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNA–vaccinated and nonvaccinated individuals in …
…, M Brisson, C Sauvageau, N Brousseau… - JAMA network …, 2022 - jamanetwork.com
Importance The Omicron variant is phylogenetically and antigenically distinct from earlier
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
SARS-CoV-2 variants and the original vaccine strain. Protection conferred by prior SARS-CoV-…
Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies …
…, JR Tyson, R Gilca, N Brousseau… - Clinical Infectious …, 2022 - academic.oup.com
Background The Canadian coronavirus disease 2019 (COVID-19) immunization strategy
deferred second doses and allowed mixed schedules. We compared 2-dose vaccine …
deferred second doses and allowed mixed schedules. We compared 2-dose vaccine …
Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12–14 months versus 15 months of age
…, N Boulianne, F Defay, N Brousseau… - Clinical infectious …, 2012 - academic.oup.com
Background. In 2011, >750 cases of measles were reported in Quebec, Canada, where a
routine 2-dose measles immunization schedule, in which measles vaccine is given at 12 and …
routine 2-dose measles immunization schedule, in which measles vaccine is given at 12 and …
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
…, M Brisson, C Sauvageau, N Brousseau… - medRxiv, 2022 - medrxiv.org
Importance Omicron is phylogenetically- and antigenically-distinct from earlier SARS-CoV-2
variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection …
variants and the original vaccine strain. Protection conferred by prior SARS-CoV-2 infection …
[HTML][HTML] Increase of invasive pneumococcal disease in children temporally associated with RSV outbreak in Quebec: a time-series analysis
…, R Gilca, C Quach, N Brousseau… - The Lancet Regional …, 2023 - thelancet.com
Background Respiratory viruses have been previously suspected to trigger invasive
pneumococcal disease (IPD). After progressive non-pharmaceutical interventions (NPI) lifting, an …
pneumococcal disease (IPD). After progressive non-pharmaceutical interventions (NPI) lifting, an …
[HTML][HTML] Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test …
…, M Brisson, C Sauvageau, N Brousseau… - The Lancet Healthy …, 2023 - thelancet.com
Background Older adults (aged ≥60 years) were prioritised for COVID-19 booster vaccination
due to severe outcome risk, but the risk for this group is also affected by previous SARS-…
due to severe outcome risk, but the risk for this group is also affected by previous SARS-…
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec …
Introduction In Canada, first and second doses of mRNA vaccines against SARS-CoV-2
were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains …
were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains …